Rathnasinghe, Raveen
Chang, Lauren A. http://orcid.org/0000-0002-3287-3987
Pearl, Rebecca
Jangra, Sonia
Aspelund, Amy
Hoag, Alaura
Yildiz, Soner
Mena, Ignacio http://orcid.org/0000-0001-5464-7086
Sun, Weina http://orcid.org/0000-0002-2435-5047
Loganathan, Madhumathi http://orcid.org/0000-0002-3751-8036
Crossland, Nicholas Alexander
Gertje, Hans P.
Tseng, Anna Elise http://orcid.org/0000-0003-4791-374X
Aslam, Sadaf http://orcid.org/0000-0002-3748-4227
Albrecht, Randy A. http://orcid.org/0000-0003-4008-503X
Palese, Peter http://orcid.org/0000-0002-0337-5823
Krammer, Florian http://orcid.org/0000-0003-4121-776X
Schotsaert, Michael http://orcid.org/0000-0003-3156-3132
Muster, Thomas
García-Sastre, Adolfo http://orcid.org/0000-0002-6551-1827
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (G20AI174733, P01AI097092, 75N93021C00014, 75N93019C00051, 75N93019C00051, R21AI176069, R21AI151229, R01AI141226)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 20 December 2023
Accepted: 19 August 2024
First Online: 16 September 2024
Competing interests
: The A.G.-S. laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck. A.G.-S. has consulting agreements for the following companies involving cash and/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer and Prosetta. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott and AstraZeneca. A.G.-S. and P.P. are inventors on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York. The M.S. laboratory has received unrelated funding support in sponsored research agreements from Phio Pharmaceuticals, 7Hills Pharma, ArgenX, and Moderna. The Icahn School of Medicine at Mount Sinai has filed patent applications regarding influenza virus vaccines on which F.K. is listed as inventor. The Krammer laboratory has received support for influenza virus research in the past from GSK and is currently receiving support from Dynavax. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to influenza virus vaccines and therapeutics vaccines, which lists F.K. as co-inventor. Several of these patents have been licensed and F.K. has received royalty payments from commercial entities. F.K. has consulted from Merck, Pfizar, Seqirus, GSK and Curevac and is currently consulting for Gritstone, 3rd Rock Ventures and Avimex and he is co-founder and scientific advisory board member of Castlevax. The F.K. laboratory is also collaborating with Dynavax on influenza virus vaccine development and with VIR on influenza therapeutics. T.M. is inventor on patents and patent applications on vaccines and immunotherapies, owned by Vivaldi Biosciences and BlueSky Immunotherapies. T.M. owns stocks and options from BlueSky Immunotherapies, Nuvonis Technologies and Vivaldi Biosciences. A.A. is inventor on patents and patent applications on vaccines and immunotherapies, owned by Vivaldi Biosciences and BlueSky Immunotherapies. A.A. owns stock options from Vivaldi Biosciences. All other authors declare no competing interests.